Vernal Keratoconjunctivitis

Harrow has announced an exclusive out-licensing agreement with Apotex, a major Canadian pharmaceutical company, to market and distribute five of the company’s branded ophthalmic products.

DENVER – Santen announced the U.S. availability of Verkazia for the treatment of vernal keratoconjunctivitis in children and adults during the ARVO meeting.

The FDA has approved a new drug application for Verkazia for the treatment of vernal keratoconjunctivitis in children and adults, according to a press release from Santen Pharmaceutical Co.

The FDA has accepted Santen’s new drug application for cyclosporine topical ophthalmic emulsion 0.1% to treat patients aged 4 to 18 years with severe vernal keratoconjunctivitis, according to a press release.